Luigi Daniele Notarangelo
Senior Investigator
Immune Deficiency Genetics Section
National Institute of Allergy and Infectious Diseases, National Institutes of Health;Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health
关注
立即认领
分享
关注
立即认领
分享
基本信息
浏览量:322
职业迁徙
个人简介
Research Topics
The main goal of the Immune Deficiency Genetics Section (IDGS) is to characterize the molecular and cellular mechanisms underlying primary immune deficiencies, and combined immunodeficiencies (CID) in particular, with the ultimate objective of improving diagnosis and treatment of these conditions.
In addition to increased susceptibility to infections, patients with CID often manifest immune dysregulation, with autoimmune cytopenias and organ-specific autoimmunity. We study both patients with yet genetically undefined forms of CID and patients with known gene defects. In the former group of patients, we use unbiased genomic approaches (whole exome sequencing) and a wide array of cellular and molecular techniques (flow cytometry; in vitro assays to explore the function of T, B, and NK cells; high-throughput analysis of T- and B-cell repertoire; analysis of a broad panel of autoantibodies; generation and targeted differentiation of induced pluripotent stem cells) to identify novel gene defects. Using this approach, the laboratory has identified several new gene defects, including DOCK2 deficiency, TTC7A deficiency (responsible for combined immune deficiency and intestinal atresias), HOIP deficiency (a cause of immune deficiency and autoinflammatory disease), and EXTL3 deficiency (associating severe T-cell immunodeficiency, skeletal dysplasia, and neurodevelopmental delay). The laboratory has a strong interest in defining the molecular and cellular defects in newborns identified with T-cell lymphopenia after newborn screening at birth.
We also aim to define the mechanisms underlying immune dysregulation in patients with CID of known genetic etiology. In this regard, the laboratory has a special interest in human RAG deficiency and in other defects of V(D)J recombination. Using a powerful in vitro platform, we have determined that the severity of clinical manifestations associated with mutations in the RAG, DCLRE1C, and LIG4 genes correlates with the residual activity of the mutant protein and with different degrees of perturbation of T- and B-cell repertoire diversity and composition. Ongoing work in the laboratory is focused on testing the hypothesis that mutations in the coding flank sensitive region of RAG1 (that interacts also with coding regions of the immunoglobulin and T-cell receptor genes) may alter selection of V, D, and J genes targeted for rearrangement and thereby alter repertoire composition, causing a breakage of tolerance. To this purpose, we take advantage of a large collaboration with other investigators at the Laboratory of Clinical Infectious Diseases within NIAID, as well as with several groups worldwide. These human studies are complemented by similar efforts in novel animal models. In particular, we have used CRISPR to generate mouse models with hypomorphic mutations in the coding flank sensitive region of Rag1, whose phenotype includes immunodeficiency and autoimmunity.
Finally, the laboratory has developed a large repository of induced pluripotent stem cells (iPSCs) from patients with CID and with other immune deficiencies. By attempting targeted differentiation of control- and patient-derived iPSCs, we aim to define the pathophysiology of immune and extra-immune manifestations of disease, as already shown by our group for reticular dysgenesis, RAG deficiency, defects of non homologous end joining, and EXTL3 deficiency. The laboratory is interested in applying CRISPR technology to correct the gene defect in patient hematopoietic stem cells and iPSCs, as a first step toward a future therapeutic use of this strategy.
The main goal of the Immune Deficiency Genetics Section (IDGS) is to characterize the molecular and cellular mechanisms underlying primary immune deficiencies, and combined immunodeficiencies (CID) in particular, with the ultimate objective of improving diagnosis and treatment of these conditions.
In addition to increased susceptibility to infections, patients with CID often manifest immune dysregulation, with autoimmune cytopenias and organ-specific autoimmunity. We study both patients with yet genetically undefined forms of CID and patients with known gene defects. In the former group of patients, we use unbiased genomic approaches (whole exome sequencing) and a wide array of cellular and molecular techniques (flow cytometry; in vitro assays to explore the function of T, B, and NK cells; high-throughput analysis of T- and B-cell repertoire; analysis of a broad panel of autoantibodies; generation and targeted differentiation of induced pluripotent stem cells) to identify novel gene defects. Using this approach, the laboratory has identified several new gene defects, including DOCK2 deficiency, TTC7A deficiency (responsible for combined immune deficiency and intestinal atresias), HOIP deficiency (a cause of immune deficiency and autoinflammatory disease), and EXTL3 deficiency (associating severe T-cell immunodeficiency, skeletal dysplasia, and neurodevelopmental delay). The laboratory has a strong interest in defining the molecular and cellular defects in newborns identified with T-cell lymphopenia after newborn screening at birth.
We also aim to define the mechanisms underlying immune dysregulation in patients with CID of known genetic etiology. In this regard, the laboratory has a special interest in human RAG deficiency and in other defects of V(D)J recombination. Using a powerful in vitro platform, we have determined that the severity of clinical manifestations associated with mutations in the RAG, DCLRE1C, and LIG4 genes correlates with the residual activity of the mutant protein and with different degrees of perturbation of T- and B-cell repertoire diversity and composition. Ongoing work in the laboratory is focused on testing the hypothesis that mutations in the coding flank sensitive region of RAG1 (that interacts also with coding regions of the immunoglobulin and T-cell receptor genes) may alter selection of V, D, and J genes targeted for rearrangement and thereby alter repertoire composition, causing a breakage of tolerance. To this purpose, we take advantage of a large collaboration with other investigators at the Laboratory of Clinical Infectious Diseases within NIAID, as well as with several groups worldwide. These human studies are complemented by similar efforts in novel animal models. In particular, we have used CRISPR to generate mouse models with hypomorphic mutations in the coding flank sensitive region of Rag1, whose phenotype includes immunodeficiency and autoimmunity.
Finally, the laboratory has developed a large repository of induced pluripotent stem cells (iPSCs) from patients with CID and with other immune deficiencies. By attempting targeted differentiation of control- and patient-derived iPSCs, we aim to define the pathophysiology of immune and extra-immune manifestations of disease, as already shown by our group for reticular dysgenesis, RAG deficiency, defects of non homologous end joining, and EXTL3 deficiency. The laboratory is interested in applying CRISPR technology to correct the gene defect in patient hematopoietic stem cells and iPSCs, as a first step toward a future therapeutic use of this strategy.
研究兴趣
论文共 1147 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Clinical Immunology (2024): 110054
Alexandra Grier,Marita Bosticardo,Francesca Pala,Kayla Amini, Eduardo Anaya,Luigi Notarangelo,Jennifer Heimall
The Journal of allergy and clinical immunologyno. 5 (2024): 1423-1431.e2
Vasileios Oikonomou,Grace Smith,Gregory M. Constantine,Monica M. Schmitt,Elise M.N. Ferré,Julie C. Alejo, Deanna Riley,Dhaneshwar Kumar, Lucas Dos Santos Dias,Joseph Pechacek,Yannis Hadjiyannis, Taura Webb,
New England Journal of Medicineno. 20 (2024): 1873-1884
Ravichandra Tagirasa, HyeSun Kueh,Marita Bosticardo,Francesca Pala,Kayla Amini, Eduardo Anaya,Jennifer Stoddard,Julie Niemela,Laia Alsina, Mario Framil Seoane,Dimana Dimitrova,Matias Oleastro,
MICROORGANISMSno. 2 (2024): 394
Journal of clinical immunologyno. 2 (2024): 53-53
Hye Sun Kuehn,Inga S. Sakovich,Julie E. Niemela,Agustin A. Gil Silva,Jennifer L. Stoddard,Ekaterina A. Polyakova, Ana Esteve Sole,Svetlana N. Aleshkevich,Tatjana A. Uglova,Mikhail V. Belevtsev, Vladislav R. Vertelko,Tatsiana V. Shman,
The Journal of clinical investigationno. 3 (2024)
Marie Materna,Ottavia M Delmonte,Marita Bosticardo,Mana Momenilandi,Peyton E Conrey,Bénédicte Charmeteau-De Muylder,Clotilde Bravetti, Rebecca Bellworthy,Axel Cederholm,Frederik Staels, Christian A Ganoza,Samuel Darko,
Science (New York, N.Y.)no. 6686 (2024): eadh4059-eadh4059
加载更多
作者统计
#Papers: 1169
#Citation: 58011
H-Index: 117
G-Index: 216
Sociability: 9
Diversity: 0
Activity: 7
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn